Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Purpose To assess and compare the therapeutic efficacy of Liraglutide, Tirzepatide, and Retatrutide in treating diabetic kidney disease (DKD) in db/db mice. Methods Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks. Subsequently, we assessed the effectiveness of these three drugs in controlling blood glucose levels, reducing weight, and improving serum biochemical indicators and DKD. Additionally, we measured and compared the renal inflammation and fibrosis indexes. Meanwhile, the content of intestinal metabolite butyrate was compared to reflect the regulatory effects of these three drugs on gut microbiota. Results Retatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide. Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice. Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs. Unfortunately, despite its ability to lower blood glucose levels, Retatrutide did not outperform the other two drugs…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings strongly indicate that all three drugs are effective in reducing food intake and promoting weight loss, with retatrutide demonstrating the most significant impact.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“Regarding HbA1c levels, retatrutide showed lower levels than those in the db/db group.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“At the end of the experiment, the weight of mice in the db/db + Reta group decreased, and at 10 weeks, db/db + Reta group mice had the lowest levels of body weight and food intake, followed by db/db + Tirz group and db/db + Lira group, with a statistically significant difference.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“Finally, after immunohistochemical analysis, retatrutide exhibited lower expression levels of inflammatory and fibrotic mediators compared to tirzepatide and liraglutide, highlighting its potential in the treatment of diabetic kidney disease.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“At 8 weeks of age, the mice were randomly divided into 5 groups (each n = 6): db/m, db/db, db/db + Lira, db/db + Tirz, and db/db + Reta.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Despite the current clinical use of renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose cotransporter 2 inhibitors (SGLT2is) [2, 3] in the treatment of DKD, progressive decline in renal function persists among numerous patients.”
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Additionally, another clinical trial involving obese or overweight patients revealed that Tir-zepatide effectively reduced body weight and improved cardiorenal risk factors, encompassing blood glucose levels, blood pressure, glycated hemoglobin, and albumi-nuria [17].”
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“However, the ef fi cacy of GLP-1RAs alone is hindered by dose-dependent gastrointestinal adverse events [5, 6], and often leads to poor tolerance or inadequate ef fi cacy in patients with type 2 diabetes mellitus (T2DM) [7, 8].”
Trajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 346
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“In previous clinical trials exploring cotadutide, a GLP-1/GCG dual agonist, reductions in both HbA1c levels and body weight were observed [34].”
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316 · cited 1×
“Furthermore, it has exhibited superiority over Tirzepatide in reducing body weight in obese mice [19].”
Cited by
Ullah, A., & Shen, B. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118065 · Cited by 48
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“Another study by Ma et al. aimed to compare the effects of retatrutide, liraglutide, and tirzepatide on diabetic kidney disease in db/db mice [41].”
Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10
Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease
Ma, J., Tao, M., Zhang, W., Zhou, L., Zhang, H., Li, F., Zhang, H., Yao, D., Lu, W., & Wang, M. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1715024 · Cited by 12
Self-citationObesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
Metadata
- Authors
- Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W.
- Affiliations
- Huaian First People’s Hospital (CN)
- Corresponding author
- Wang, Min
- Lu, Weiping
- Venue
- Endocrine
- Published
- 2024-08-30
- Volume
- 87
- Issue
- 1
- Pages
- 159-169
- ISSN
- 0969-711X (ISSN-L)
- 1559-0100
- OpenAlex
- W4402061935
- Cited by
- 21
- References
- 36
- Citations by year
- 2026: 10 · 2025: 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Development Fund of the Affiliated Hospital of Xuzhou Medical University (No. XYFY2021031.)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, liraglutide, tirzepatide, retatrutide, db/db mice, renal fibrosis, renal inflammation, butyrate, gut microbiota, intestinal metabolites, glycemic control, weight loss, lipid metabolism, inflammatory cytokines, NLRP3 inflammasome, caspase-1, fibronectin, type 2 diabetes
- MeSH terms
- Gastrointestinal Microbiome, Liraglutide, Tirzepatide, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Fatty Acids, Hypoglycemic Agents, Kidney, Male, Mice, Inbred C57BL, Peptides, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. https://app.cochat.ai/papers/10.1007/s12020-024-03998-8
- The paper
- Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W. (2024). Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. https://doi.org/10.1007/s12020-024-03998-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.